Patents Assigned to Celgene Quantical Research, Inc.
  • Histone demethylase inhibitors
    Patent number: 9873697
    Abstract: The present invention relates generally to compositions and methods for treating cancer and neoplastic disease. Provided herein are substituted pyrrolopyridine derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition of histone demethylase. Furthermore, the subject compounds and compositions are useful for the treatment of cancer, such as prostate cancer, breast cancer, bladder cancer, lung cancer and/or melanoma and the like.
    Type: Grant
    Filed: July 17, 2017
    Date of Patent: January 23, 2018
    Assignee: Celgene Quantical Research, Inc.
    Inventors: Young K. Chen, Michael Brennan Wallace
  • Histone demethylase inhibitors
    Patent number: 9738637
    Abstract: The present invention relates generally to compositions and methods for treating cancer and neoplastic disease. Provided herein are substituted pyrrolopyridine derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition of histone demethylase. Furthermore, the subject compounds and compositions are useful for the treatment of cancer, such as prostate cancer, breast cancer, bladder cancer, lung cancer and/or melanoma and the like.
    Type: Grant
    Filed: March 11, 2014
    Date of Patent: August 22, 2017
    Assignee: Celgene Quantical Research, Inc.
    Inventors: Young K. Chen, Michael Brennan Wallace
  • Histone demethylase inhibitors
    Patent number: 9714230
    Abstract: Provided herein are substituted pyrazolylpyridine, pyrazolylpyridazine, and pyrazolylpyrimidine derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition histone demethylase. Furthermore, the subject compounds and compositions are useful for the treatment of cancer, such as prostate cancer, breast cancer, bladder cancer, lung cancer and/or melanoma and the like.
    Type: Grant
    Filed: August 8, 2016
    Date of Patent: July 25, 2017
    Assignee: Celgene Quantical Research, Inc.
    Inventors: Zhe Nie, Jeffrey Alan Stafford, James Marvin Veal, Michael Brennan Wallace
  • Histone demethylase inhibitors
    Patent number: 9643965
    Abstract: The present invention relates generally to compositions and methods for treating cancer and neoplastic disease. Provided herein are substituted pyrido[3,4-d]pyrimidin-4-one derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition of histone demethylase. Furthermore, the subject compounds and compositions are useful for the treatment of cancer, such as prostate cancer, breast cancer, bladder cancer, lung cancer and/or melanoma and the like.
    Type: Grant
    Filed: September 16, 2015
    Date of Patent: May 9, 2017
    Assignee: Celgene Quantical Research, Inc.
    Inventors: Amogh Boloor, Toufike Kanouni, Jeffrey Alan Stafford, James Marvin Veal, Michael Brennan Wallace